| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7230012 | CELGENE | Pharmaceutical compositions and dosage forms of thalidomide |
Dec, 2023
(2 months from now) | |
Thalomid is owned by Celgene.
Thalomid contains Thalidomide.
Thalomid has a total of 1 drug patent out of which 0 drug patents have expired.
Thalomid was authorised for market use on 16 July, 1998.
Thalomid is available in capsule;oral dosage forms.
The generics of Thalomid are possible to be released after 09 December, 2023.
Drugs and Companies using THALIDOMIDE ingredient
Market Authorisation Date: 16 July, 1998
Treatment: NA
Dosage: CAPSULE;ORAL
How can I launch a generic of THALOMID before it's drug patent expiration?
More Information on Dosage
THALOMID family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic